Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Mumbo
Thank you. My risk appetite is not as moderate as it should be. Just made a bit on Argo so perhaps - if I make a bit more - NRXP is the destination. Will have a good look. Thank you very much. :)
Yes thanks Nolupus
Thats why I like SAREUM. Nothing at SAR is in late stage trials so there's less chance of a complete sp disaster. Which means there's time to trade and de-risk. SYN was always harder for me because I came in so late. Getting into one's chosen pharma early - that must be the way.
Point well made Nolupus.
Punt with only what you can afford to lose. SNG cash position is what 40 million once P3 is done I believe. We are looking at SP crashing to 20-30p. It’s what happened to Atea, it’s sitting little above the cash position.
What’s your risk appetite xviolet?
If you are looking at something that can do 10X in the next few months….. take a look at NRXP on Nasdaq. Covid treatment that made it to active phase 3 like SNG. Their own phase 3 reports by end of 2021.
Fraught with risk, and lots of shenanigans in-house. Partner company is taking nrxp to court for breach of contract… despite that lot of upside if it comes good. DYOR.
I haven’t taken a position but will do so. It was on my list to get in after Atea results. Since that imploded early, nrxp in focus.
Bojo2020,
I tend to agree that at the present level of valuation and the current sentiment towards covid stocks, SNG is now in a less favorable risk/ reward ratio than before …
SNG is the number one stock for many of the new ´ covid ´ investors and has a major cult following but it reminds me ( a bit too much ) of IMM before P3 read outs ( but without the company ramping )
The major factor one has to take into account is what has SNG to fall back on in case the P3 trials don’t live up to expectations ?
Worth a punt but one has to be aware of their money management and be prepared to lose 50-70% of the investment if things go bad …
One can lose profits , that’s not a problem but when one loses their capital well that’s a different story so be safe …
Doesn't have to be a pharma.
I would nominate EISB.
I want to find the next SNG and get in early! And buy at wholesale prices!
And quietly wait 2-10 years, if necessary.
Suggestions appreciated.
Bearing in mind that we have different strategies as I don’t hold all the way through trials.
July 2020 saw stage/phase 2 results that propelled the synairgen share price up between 600 and 800% (dependant on a persons average). In my view, positive data from a trial will propel a share price far higher than announcement a trial is underway. This is proving to be the case with SNG at the moment and it is making people nervous. The big gains have already been made last year. Although small gains are appearing currently as people take positions for the final stage. I think it will fall into a zone between £1.45 and £1.70 until news.
I would go as far as to say that I personally would avoid p3 trials for this reason; If it has built a share price following positive phase 1 and 2, it should already be highly valuable. If it were then to fail at phase 3, it would be a long way to fall with no or little chance of a comeback.
This is my approach to phase trails and I will be adopting the same strategy to a Sclp and the others I hold.
This is not a deramp of SNG, it will probably get there.
I disagree that Phase 3 is the highest risk, for me that’s stage 2. With it getting to stage 3, I see it derisked financially as long as you are prepared to be patient if you believe in the product. Same applies to AGL and I am in them both. Just my opinion.
BOJO2020
That is a lot to think about. I can't see the light on SYN. I don't have the experience. I'll sell some (in case the price slides). And keep some (in case something good happens).
Not sure what you all think, but phase 3 holds the highest risk? That’s why the market reaction is muted. This could be stuck in a zone for a long while yet. This may become the albatross around Sngs neck much like FDA with Angle. Both need to pass these milestones in order to unlock further value.
Well at last done Synairgen news. I had hoped to get rid of one of my SNG holdings but the rise wasn’t what I had hoped for so I have continued to hold both of them. Perhaps the news will take a few days to filter! I have also been watching Entain is anybody else invested?